This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Ischemia; reperfusion injury	Macrophage migration inhibitory factor (MIF)	<p>Studies in rats suggest that MIF-binding benzothiazin-4-one derivatives could help prevent ischemia and reperfusion injury. In a rat model of ischemia and reperfusion injury, one of the derivatives led to about 45% smaller infarct sizes than vehicle controls ($p=0.0013$). In cultured cardiomyocytes, a second benzothiazin-4-one derivative bound MIF and activated gene expression to prevent apoptosis compared with no treatment. Next steps include testing whether the derivatives can prevent compensatory cardiac hypertrophy from progressing to heart failure.</p> <p>Takeda Pharmaceutical Co. Ltd. did not disclose the developmental status of its benzothiazin-4-one derivatives program.</p> <p>SciBX 4(3); doi:10.1038/scibx.2011.69 Published online Jan. 20, 2011</p>	Patent application filed; unavailable for licensing	<p>Kimura, H. <i>et al. Chem. Biol.</i>; published online Dec. 22, 2010; doi:10.1016/j.chembiol.2010.10.011</p> <p>Contact: Haruhide Kimura, Takeda Pharmaceutical Co. Ltd., Osaka, Japan e-mail: kimura_haruhide@takeda.co.jp</p>